Objectives: We sought to estimate the mortality and morbidity in diabetic acute heart failure (AHF) patients stratified by left ventricular ejection fraction. Methods: We analyzed the data of patients with AHF from seven Middle Eastern countries (Bahrain, Oman, Yemen, Kuwait, UAE, Qatar, and Saudi Arabia) from February to November 2012, who were enrolled in a multinational registry of patients with heart failure (HF). Results: A total of 2258 AHF patients had diabetes mellitus. The mean age was 63.0±11.0 years (ranging from 18 to 99 years), and 60.3% (n = 1362) of the patients were males. The mean ejection fraction (EF) was 37.0±13.0%. HF with reduced EF (< 40%) (HFrEF) was observed in 1268 patients (56.2%), whereas 515 patients (22.8%) had mid-range (40-49%) (HFmrEF) and 475 patients (21.0%) had preserved EF (≥ 50%) (HFpEF). The overall cumulative all-cause mortalities at three-and 12-months follow-up were 11.8% (n = 266) and 20.7% (n = 467), respectively. Those with HFpEF were associated with lower three-months cumulative all-cause mortality compared to those with HFrEF (7.6% vs. 5.9%; adjusted odds ratio (aOR) = 0.54, 95% confidence interval (CI): 0.31-0.95; p = 0.031), but not significantly different when compared to those with HFmrEF (aOR = 0.86, 95% CI: 0.53-1.40; p = 0.554). There were largely no significant differences among the groups with regards to the 12-months all-cause cumulative mortality (11% vs. 11% vs. 10%; p = 0.984). There were also no significant differences in re-hospitalization rates between the three HF groups not only at three months (23% vs. 20% vs. 22%; p = 0.520), but at one-year follow-up (28% vs. 30% vs. 32%; p = 0.335). Conclusions: Three-month cumulative all-cause mortality was high in diabetic HFrEF patients when compared to those with HFpEF. However, there were no significant differences in mortality at one-year follow-up between the HF groups. There were also no significant differences in re-hospitalization rates between the HF groups not only at three months but also at one-year follow-up in the Middle East.
T he rising prevalence of diabetes mellitus (dM) in heart failure (HF) patients is becoming a global burden. It is a more frequently coexisting risk factor for incident HF, given its increasing role in morbidity and mortality. 1 Reports of its coexistence in HF range from 10% to 47%. [2] [3] [4] The optimal therapeutic approach to dM (especially type 2) has gained much importance in the recent past. Early introduction of sodium-glucose transport protein 2 (SGlT2) inhibitors in the treatment strategy seems beneficial to reduce frequent HF-related hospitalizations. The coexistence of both dM and HF warrants a multidisciplinary approach in such patients. The importance of lifestyle modifications along with glucose-lowering agents plays a major role in achieving better outcomes in HF patients with dM. 5 The risk of HF in patients with dM is more evident in women and young adults. 6 The risk of developing HF in dM is multifactorial and is mainly related to poor glycemic control, older age, obesity, hypertension, and coronary artery disease (CAd). 7 There is scant data on the morbidity and mortality of HF patients with dM stratified by left ventricular ejection fraction (lVEF) in the Arabian Gulf. Hence, we sought to evaluate the morbidity and mortality of diabetic HF patients in the Arabian Gulf stratified by lVEF.
M ET H O D S
We used the data from a prospective, multicenter, multinational registry of acute heart failure (AHF) patients admitted to 47 hospitals in seven Middle Eastern countries (Bahrain, Oman, Qatar, UAE, Kuwait, Saudi Arabia, and Yemen). The methods of Gulf Acute Heart Failure Registry (CARE) have been published previously. 8 In summary, demographic and clinical characteristics, as well as outcomes, were captured. Follow-up for allcause mortality and re-hospitalization history were collected via telephone at three-months and either via telephone or through outpatient clinic visits at one-year. The registry is listed on clinicaltrials.gov (number NCT01467973).
data entry was carried out online using a custom-designed electronic case-record form (CRF) at the Gulf CARE website (www.gulfcare. org ). Institutional ethical committee approvals were obtained. Trained abstractors collected the data from medical records at each participating site, and this information was recorded using an electronic CRF.
AHF was defined, according to the European Society of Cardiology, 9, 10 as the rapid onset of symptoms and signs secondary to abnormal cardiac function.
HF with reduced ejection fraction (HFrEF) was diagnosed when patients with symptoms and signs of HF had a measured EF < 40%. HF with midrange EF (HFmrEF) was diagnosed when patients with symptoms and signs of HF had a measured EF between 40-49%. HF with preserved EF (HFpEF) was diagnosed when patients with symptoms and signs of HF had a measured EF between ≥ 50%. [11] [12] [13] Patients with HF that did not require admission were excluded from the registry. Furthermore, those that did not have a record of EF were also excluded from the analysis.
CAd was diagnosed if any of the following conditions were present: at least one major epicardial coronary artery determined by coronary angiography to have > 70% obstruction, history of myocardial infarction associated with wall motion abnormality seen on echocardiography or gated blood pool imaging, and/or stress testing (with or without imaging) results that are diagnostic of CAd. Hypertension was defined when any of the following conditions were present: untreated systolic blood pressure > 160 mmHg or diastolic blood pressure > 105 mmHg for at least three months and/or hypertension requiring at least two drugs for control for ≥ 5 years.
14 dM was diagnosed based on fasting plasma glucose levels (FPG) ≥ 126 mg/ dl (7.0 mmol/l), two-hour plasma glucose levels (2-h PG) ≥ 200 mg/dl (11.1 mmol/l) during oral glucose tolerance test, and glycated hemoglobin A1c (HbA 1c ) ≥ 6.5% (48 mmol/mol). 15 descriptive statistics were used to present the data. Categorical variables were summarized as frequencies and percentages and analyzed using Pearson's chi-squared test. Continuous variables were summarized using means and standard deviations and analysis performed using ordinary least squares regression.
Multivariable logistic regression models, utilizing the simultaneous method, were performed to evaluate the impact of HF (HFrEF, HFmrEF, and HFpEF) on all-cause mortality and re-hospitalization (primary outcomes) at three-months and one-year post-hospital discharge. The multivariate logistic models were adjusted for significant demographic and clinical characteristics as well as medications outlined in Tables 1 and 2 . The goodness-of-fit of the multivariable logistic model was examined using the Hosmer and lemeshow goodness-of-fit statistic, and the discriminatory power of the logistic model was assessed by the area under the receiver operating characteristics curve also known as C-index. An a priori two-tailed level of significance was set at p < 0.050. Statistical analyses were conducted using STATA version 13.1 (STATA Corporation, College Station, TX, USA).
R E SU LTS
A total of 2258 patients with diabetes with a diagnosis of AHF were recruited to the study; 60.3% (n = The overall cumulative all-cause mortalities at three-month and 12-month follow-up were 11.8% (n = 266) and 20.7% (n = 467), respectively. Those with HFpEF were associated with lower threemonth cumulative all-cause mortality compared to those with HFrEF (7.6% vs. 5.9%; adjusted odds ratio (aOR) = 0.54, 95% confidence interval (CI): 0.31-0.95; p = 0.031) but not significantly different when compared to those with HFmrEF (aOR = 0.86, 95% CI: 0.53-1.40; p = 0.554). There were no significant differences among the groups with regards to the 12-month all-cause cumulative mortality (11% vs. 11% vs. 10%; overall p = 0.984). There were also no significant differences in re-hospitalization rates between the three HF groups not only at threemonths (23% vs. 20% vs. 22%; overall p = 0.520), but also at one-year follow-up (28% vs. 30% vs. 32%; overall p = 0.335) [ Table 3 ].
D I S C U S S I O N
The observations from this multinational registry showed that three-month cumulative all-cause mortality was high in diabetic HFrEF patients compared to those with HFpEF. However, there were no significant differences in mortality at oneyear follow-up between the HF groups. There were also no significant differences in re-hospitalization rates between the HF groups not only at threemonths but also at one-year follow-up in the Middle East.
In the Framingham Heart Study, the risk of incident HF was two-fold higher in diabetic males and four-folds higher in diabetic females. 16 The study has also shown a 34% mortality at one-year for diabetic HF patients. 17 In the Heart and Soul Study in a cohort of CAd patients with dM were associated with a higher risk of incident HF. 18 The risk of incident HF rises from 8% to 36% with each 1% rise in HbA 1c . 19 The Atherosclerosis Risk in Communities (ARIC) study has shown rising HF-related hospitalization rates with increases in HbA 1c . 20 Various other studies have also documented poor outcomes in patients with HF and with elevated HbA 1c . 21 In another study that consists of 18 084 non-diabetic patients with a higher risk of cardiovascular diseases has also shown that a mild increase in blood glucose of 1 mmol/l increases the risk of hospitalization by 1.23-fold. 22 In the Candesartan in Heart failure-Assessment of moRtality and Morbidity (CHARM) trial, the rate of hospitalizations was higher in patients with HFpEF than in those with HFrEF. Furthermore, the observed all-cause mortality risk in patients with dM was the same in both HFrEF and HFpEF. 23 In acute HF patients, the presence of dM increases mortality in both ambulatory and hospitalized patients. 23, 24 In another community-based study, it was shown that T2dM increases mortality and morbidity in both HFrEF and HFpEF. 25 In another study, a moderate difference in in-hospital mortality between HFrEF and HFpEF diabetic patients has been observed. 26 The incidence of dM was high (67%) in AHF patients with cardio-renal anemia syndrome in the Arabian Gulf. 27 A new risk calculator for HFrEF (www.hfriskcalc.in) has been suggested. 28, 29 Many HF risk models take dM as an important variable and consider it as an independent risk factor for predicting mortality. 30 In the Antihypertensive and lipid-lowering Treatment to Prevent Heart Attack (AllHAT) trial, the presence of diabetes had shown a two-fold rise in mortality and morbidity. 31 In the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) trial, cardiovascular mortality and HF-related morbidity was 34% in diabetic HF patients. 32 The Studies of left Ventricular dysfunction (SOlVd) trial also demonstrated higher rates of hospitalizations and mortality in asymptomatic ischemic cardiomyopathy patients with diabetes. 33 The same study also showed that African-Americans with HFrEF were at higher risk of developing AHF compared to Caucasians. 34 A meta-analysis of eight trials demonstrated that the risk of HF remains same in both strict the glycemic control group and standard treatment group. 35 Many randomized controlled trials have shown that in diabetic HF patients, strict glycemic control has no benefits in terms of outcome. 36 In the Arabian Gulf, the AHF patients were a decade younger compared to those from the rest of the world. 37 The dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 (dEClARE-TIMI 58) trial has shown mortality and morbidity benefits in diabetic HF patients on dapagliflozin treatment. 38 In a study of black diabetic cardiomyopathic patients, a reduced stroke and enddiastolic volume were associated with an increased left ventricular mass. 39 In the Empagliflozin Cardiovascular Outcome Event (EMPA-REG) trial, HF-related hospitalizations were associated with those treated with SGlT2 inhibitors. 40 In the Saxagliptin Assessment of Vascular Outcomes Recorded (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 trial, the use of saxagliptin was associated with an increased risk of HF hospitalizations. 41 Middle East data on diabetic and non-diabetic AHF patients showed no significant differences in all-cause mortality and rehospitalizations at three and 12 months. 42 In HF and diabetes, genetics plays an important role and further studies are needed. 43, 44 Various limitations of this registry are noteworthy. In some countries, only a few hospitals took part in the registry; hence, the results might not be entirely generalizable. Since this study was derived from a HF registry in the Arabian Gulf, it is unfortunate that diabetic medications were not captured. Mortality rates at three-months and one-year follow-up were only recorded without the specification of the exact date of death of each patient. Hence, survival analysis, which might have been more appropriate, could not have been performed. Future studies need to overcome these limitations.
C O N C LU S I O N
Three-month cumulative all-cause mortality was high in diabetic HFrEF patients compared to those with HFpEF. However, there were no significant differences in mortality at one-year follow-up between the HF groups in the Middle East. There were also no significant differences in re-hospitalization rates between the HF groups not only at three-months but also at one-year follow-up.
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